Login to Your Account

Clinic Roundup

Thursday, May 23, 2013

• Agenus Inc., Lexington, Mass., started enrollment of a Phase II study with Prophage G-200 (heat shock protein peptide complex-96 or HSPPC-96) vaccine in combination with Avastin (bevacizumab, Genentech/Roche) for treatment of recurrent glioblastoma multiforme in adult patients.

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription